Loading clinical trials...
Loading clinical trials...
The Effect of Repeat Dosing of Imlunestrant on CYP3A Activity in Healthy Women of Non-childbearing Potential
Conditions
Interventions
Midazolam
Imlunestrant
Locations
2
United States
LabCorp CRU, Inc.
Daytona Beach, Florida, United States
LabCorp CRU, Inc.
Dallas, Texas, United States
Start Date
September 12, 2022
Primary Completion Date
November 30, 2022
Completion Date
November 30, 2022
Last Updated
November 12, 2025
NCT06716502
NCT07310264
NCT06290258
NCT00090662
NCT07483606
NCT07310901
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions